Investigators examine long-term effects of anti-VEGF injection on renal function


The study found no association between treatment and the risk of chronic kidney disease or end-stage renal disease.

Investigators examine long-term effects of anti-VEGF injection on renal function

Dr Daniel Choi and colleagues from the University of Pennsylvania, Philadelphia, investigated the effect of anti-vascular endothelial growth factor (VEGF) therapies in patients over the long term and overall found no association between the treatments and the risk of chronic kidney disease or end-stage renal disease.

They commented that while intravitreal anti-VEGF can reduce plasma-free-VEGF, the literature contains little information on the safety of long-term intravitreal anti-VEGF injections on the body and especially the kidney.

In this study, the investigators used a commercial and Medicare Advantage medical claims database to identify patients who had been treated with an intravitreal anti-VEGF agent and the numbers of injections administered over 4 years after the initial injection. The patients who met the inclusion criteria were divided into quartiles based on the number of injections they received, and the highest and lowest quartiles were compared.

The authors also looked at individual diseases, i.e., neovascular age-related macular degeneration (AMD), macular oedema associated with retinal vein occlusion (RVO), and diabetic retinopathy (DR). They also used Cox proportional regression analysis to assess an every-5-injection increase in the hazard of developing kidney disease, they described.

Results of analysis

The results showed that 13,895 patients had received 1 to 3 anti-VEGF injections (lowest quartile) and 13,881 had received more than 21 or more injections (highest quartile).

In the lowest and highest quartiles, respectively, the patients with neovascular AMD received 6,228 injections (1 to 4 injections) and 6,172 had 24 or more injections (24 or more injections); those with macular oedema due to RVO, 573 (1 to 2 injections) and 580 (12 or more injections); and those with DR, 523 (1 to 2 injections) and 517 (13 or more injections).

The authors reported that for patients in the highest quartile, the weighted analysis showed no association overall with development of kidney disease (odds ratio [OR], 1.00, 95% confidence interval [CI], 0.98-1.01, P = 0.58) or in patients with neovascular AMD (OR, 0.99, 95% CI, 0.97-1.02, P = 0.48), decreased odds in macular oedema due to RVO (OR, 0.93, 95% CI, 0.86-0.99, P = 0.04), and increased odds in DR (OR, 1.12, 95% CI, 1.03-1.22, P = 0.01). Cox analysis showed no association overall or for any subgroup (hazard ratio, 0.97-1.01, P > 0.27 for all comparisons).

The authors concluded, “While logistic regression showed some association of the increased number of injections with kidney disease, the Cox analysis did not confirm these findings, suggesting time was a confounder in the logistic regression analysis.”

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.